Jeffrey Lee Boerneke, General Counsel and Secretary of Aspen Neuroscience, Inc., filed an initial statement of beneficial ownership on October 29, 2026, disclosing a stock option to purchase 101,193 shares of common stock.

Key Highlights

  • Reporting person: Jeffrey Lee Boerneke, identified as General Counsel and Secretary of Aspen Neuroscience, Inc.
  • Security disclosed: A stock option (right to buy) covering 101,193 shares of common stock, held directly.
  • Exercise price: $9.79 per share, with an expiration date of May 12, 2036.
  • Grant date: The option was granted on May 13, 2026, according to the filing's explanation of responses.
  • Vesting schedule: One-quarter of the option vests on May 7, 2027, with 1/48th vesting monthly thereafter, subject to continued service.
  • No non-derivative securities: Table I of the filing lists no directly or indirectly held non-derivative securities.

Boerneke's Initial Ownership Disclosure at Aspen Neuroscience

According to the Form 3 filed with the U.S. Securities and Exchange Commission on October 29, 2026, Jeffrey Lee Boerneke submitted his initial statement of beneficial ownership in connection with his role as General Counsel and Secretary at Aspen Neuroscience, Inc. (NASDAQ:ASPE). The filing's date of event requiring the statement is listed as October 29, 2026.

The filing discloses one derivative security in Table II: a stock option granting the right to buy 101,193 shares of common stock at an exercise price of $9.79 per share, expiring May 12, 2036. The option is held directly. The filing states that the option was granted on May 13, 2026. Per the explanation of responses, "1/4th of the option shall vest and become exercisable on May 7, 2027, and 1/48th of the option shall vest and become exercisable monthly thereafter, subject to the Reporting Person's continued service through each vesting date."

Table I, covering non-derivative securities beneficially owned, contains no entries, indicating that Boerneke reported no direct or indirect holdings of common stock or other non-derivative securities at the time of filing. The form was filed by one reporting person and is not an amendment to a prior filing.

What Was Disclosed

Boerneke's Form 3 reported an initial beneficial ownership position consisting solely of a stock option for 101,193 shares of Aspen Neuroscience common stock at $9.79 per share, granted May 13, 2026, with a four-year monthly vesting schedule beginning May 7, 2027.